CAPHRA calls for regulated access to e-cigarettes in Australia

Dec.16.2022
CAPHRA calls for regulated access to e-cigarettes in Australia
CAPHRA submits consultation document to TGA for access to legal electronic cigarettes and nicotine in Australia.

According to a submission by the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), just over 1% of people capable of writing nicotine scripts actually do so. Less than one-third of authorized prescribers are publicly available for adult smokers seeking to switch to nicotine e-cigarettes due to Australia's failed medicalized model.


CAPHRA has submitted a consultation paper to the Therapeutic Goods Administration (TGA) in Australia, discussing various options for legally obtaining electronic cigarettes and nicotine.


Australia remains the only Western democracy that requires a prescription for nicotine electronic cigarettes. The public consultation period regarding the proposed reform on the regulation of nicotine e-cigarette products in Australia began on November 30th and ended on January 16th, 2023.


Over the past decade, smoking rates in Australia have remained stable, particularly among vulnerable and disadvantaged communities. Nancy Loucas, the executive coordinator of CAPHRA, stated that "electronic cigarettes are one of the most effective methods for smokers worldwide to quit smoking, and access to them at retail outlets should have been restricted long ago.


CAPHRA stated that several countries, including the European Union, the United Kingdom, New Zealand, and Canada, are currently utilizing electronic cigarettes and reduced harm products to influence the rapid decline in smoking prevalence in these countries.


Ms. Lucas stated that the most deadly product to the public, combustible tobacco, is still readily available at any ordinary retailer, which is a mockery of public health.


Australia needs to determine whether their nicotine policy decisions are based on science, evidence, and facts to promote and maintain the health of their population, or if they choose money over health regarding tobacco consumption taxes and other possible funding they may receive due to their severe policy, which has proven to be a failure, according to CAPHRA.


Australian politicians and officials may not like to hear it, but if they want to see success, they need only cross the Tasman Sea. New Zealand has adopted an active harm reduction approach towards tobacco, and in the past decade, with the implementation of the Smokefree 2025 goal, their overall smoking rate has halved. Now they aim to achieve a regular smoking rate of only 5% or less. "Ms Loucas said.


Similarly, CAPHRA wrote that if youth access is truly a concern for Australian policymakers, the only solution is proper regulation and imposing strict fines and license revocations for non-compliant retailers. New Zealand's 2020 e-cigarette legislation and subsequent regulations achieved this.


According to Ms. Loucas, New Zealand has an effective consumer framework. In fact, in the past year alone, over 150,000 New Zealanders have switched from deadly combustible products to safer nicotine alternatives.


The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) believes that a regulated consumer market will enable Australia to have necessary control over the quality and quantity of products sold by community retailers. It also allows for products to be restricted to adults only – similar to alcohol and combustible cigarettes.


The report points out that there is currently a prevalence of unregulated black market products in Australia, with no regulatory control over their content or access for individuals under the age of 18.


We, on behalf of our nine member organizations, have submitted a letter of objection to the consultation document advocating for the 'gateway theory.' Despite the document's claim of evidence that electronic cigarettes lead to youth smoking, the gateway theory has been both confirmed and questioned by numerous international research institutions. Ms. Loucas stated that electronic cigarettes are an exit from smoking, not an entrance.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09